Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Rizaport
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Exeltis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 27, 2020
Details:
Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lidocaine,Tetracaine
Therapeutic Area: Neurology Product Name: Pliaglis
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries Ltd.
Deal Size: Undisclosed Upfront Cash: $3.9 million
Deal Type: Licensing Agreement July 28, 2020
Details:
The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rizatriptan Benzoate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
IntelGenx recently received from the U.S. FDA Complete Response Letter regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm®.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
